Full-Time
Control Engineer
Ottobock
1,001-5,000 employees
Provider of prosthetics, orthotics, wheelchairs, exoskeletons
No salary listed
Germany
In Person
 Electrical Engineering (1) |
|---|
Get referred to Ottobock
See people who can refer or advise you
- Master or PhD in Control Engineering, Biomedical Engineering, Mechatronics, Robotics or a closely related field
- 2 to 5 years of professional experience in prosthetics, orthotics, exoskeletons, portable robotics or rehabilitation robotics
- Develop, implement and validate control strategies for motorized prostheses and orthoses of the lower and upper extremities, including impedance control, admittance control, finite state machine architectures and model predictive approaches
- Translate biomechanical models of human joint function (including moment-angle-velocity envelopes, joint couplings and gait phase dynamics) into control requirements and implementable regulator structures
- Integrate AI/ML components in control pipelines: use of classification networks for activity and terrain recognition, recurrent models for gait phase prediction, and data-driven approaches for parameter adaptation
- Develop and apply state estimation methods, including Kalman Filter variants and sensor fusion algorithms, to estimate joint states, user intent and environmental context from device sensor data (IMU, force/torque, EMG, encoder)
- Design and conduct experimental validation protocols on physical hardware, including lab tests and studies with participants in collaboration with partners from clinical and biomechanics domains
- Collaborate with biomechanists and clinical partners to define functionally meaningful control targets, differentiating normalization of gait patterns from user-specific optimization goals
- Evaluate sensory feedback modalities (force, vibrotactile, proprioceptive substitution) and assess their role in closing the human-device control loop
- Document control architectures, test results and validation outcomes in technical reports
- Conduct structured literature reviews and competitive analyses to keep abreast of the state of the art in prosthetic and orthotic control, wearable robotics and human movement science
- Present results to internal stakeholders, research partners and potentially to a clinical audience
- Collaborate with regulatory and product development teams to ensure control concepts comply with applicable safety standards (EU-MDR, IEC 60601-1, ISO 13482)
Ottobock is a global producer of orthopedic technology, focusing on prosthetics, orthotics, wheelchairs, and exoskeletons. Its products range from basic devices to advanced, microprocessor-controlled prosthetics and ergonomic exoskeletons that help people move more easily and stay independent. These devices work by using sensors, motors, and smart controls to adapt to a user’s movement, pace, and terrain, providing ankle and knee assistance or full upper- and lower-limb support. compared with others, Ottobock stands out as a family-owned company with a long history, a broad international footprint in about 60 countries, a large workforce, and a strong commitment to social responsibility, including a long-running partnership with the Paralympic Games. Its core goal is to improve mobility and quality of life for people with disabilities by delivering reliable, high-quality mobility solutions.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Duderstadt, Germany
Founded
1919
Get referred to Ottobock
See people who can refer or advise you
Simplify's Take
What believers are saying
- FES acquisition from Fesia expands neuro-orthotics portfolio for rising neurological condition patients worldwide.
- RESTORE™ System investment enables intuitive prosthetic control, boosting market demand for high-end prosthetics.
- Global 400-center network delivers integrated clinical and tech services, strengthening patient loyalty and market share.
What critics are saying
- FTC-mandated divestiture of Freedom Innovations assets likely in 6–12 months, causing critical market share loss to Freedom as direct competitor.
- Ossur capturing 15% of European prosthetics market by 2027 erodes premium pricing amid intensified competition from Ossur and Willow.
- Unapproved FDA FES classification from Fesia acquisition may trigger $50M+ recall and 9-month neuro-orthotics revenue delay in 9–12 months.
What makes Ottobock unique
- Ottobock acquires Fesia Technology to expand neuro-orthotics with FES systems for stroke and spinal injury patients.
- Invests $5M in Blue Arbor to advance RESTORE™ System enabling direct neuromuscular control of prosthetics with five-year stability.
- Holds 2,110 patents and operates 400 care centers globally, leading in prosthetics, neuro-orthotics, and exoskeletons with sensor-integrated tech.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Holidays
401(k) Company Match
100% company-paid short & long-term disability
Company News
Blue Arbor Technologies has secured a $5 million investment from Ottobock, the global prosthetics leader, to advance its RESTORE Neuromuscular Interface System. Ottobock will lead Blue Arbor's Series A financing and hold a board seat. The FDA breakthrough-designated RESTORE System provides a fully implanted neuromuscular interface connecting advanced prostheses directly to patients' residual muscles and peripheral nerves. It enables independent, simultaneous control of fingers, wrist and elbow, with trials demonstrating stable signal capture for over five years. In December 2025, surgeons at the Medical University of Vienna completed the first-in-human RESTORE procedure. Within days, the patient demonstrated functional use with an Ottobock prosthetic. Founded by Drs Paul Cederna, Theodore Kung and Alex Vaskov, Blue Arbor has been awarded over $60 million in research grants and published more than 200 peer-reviewed papers.
Blue Arbor Technologies announces $5 million investment by Ottobock to advance RESTORE™ System, designed to enable intuitive prosthetic control
Onward has completed its capital round, securing €50.85 million from a group of major investors.
Ottobock SE & Co. KGaA shares have been stabilizing since their IPO on October 14, with trading starting at €66.00. The lowest price reached was €64.50 on October 17. Stabilization measures, managed by Goldman Sachs Bank Europe SE, have been conducted daily across multiple trading venues, including XETRA and the Frankfurt Stock Exchange. The base offering included 10,640,151 shares. The shares are trading under ISIN DE000BCK2223.
Ottobock SE & Co. shares rose in the prosthetics firm’s debut trading session in Frankfurt on Thursday, after the biggest initial public offering in Germany in more than a year.